SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is currently trending following the announcement of a preliminary Phase 3 trial design for its lead candidate, CAD-1005, aimed at treating Heparin-Induced Thrombocytopenia. Investors are actively debating the company's clinical prospects and reliance on event-driven catalysts, while some community members voice concerns over potential dilution risks and the influence of automated social media activity.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is driving intense community activity and speculative buying as traders anticipate a potential breakout and further price discovery. While some market participants express caution regarding volatility and project longevity, the active community remains focused on momentum and the potential for the stock to surpass previous highs.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate the conglomerate's record-breaking cash pile and lack of significant capital deployment in a surging market, leading to frustration over its lagging performance relative to major indices. While the community is actively divided between those viewing the company as a defensive anchor during potential volatility and those criticizing leadership for missed innovation opportunities, many are looking toward the upcoming annual meeting for clarity on Greg Abel's operational strategy.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending due to a wave of high-value M&A activity and positive data readouts that are fueling optimism across the sector. Investors are actively discussing the potential for sector re-ratings, with many community members highlighting specific oncology and pipeline assets as undervalued opportunities for long-term growth.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending as investors react to a major acquisition in Brazil, which significantly expands the company's rare earth mining and magnet-manufacturing capacity. The community is actively debating the stock's long-term strategic potential versus concerns regarding potential dilution from the deal, while many participants are focused on the stock's technical momentum and its role in a broader domestic supply chain independence narrative.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle Mexican Grill is facing intense investor frustration as the stock struggles with downward pressure despite recent earnings efforts and expansion plans. The community is actively debating the effectiveness of current leadership and management strategies, frequently comparing the brand's lackluster performance and service quality to more agile competitors in the fast-casual sector.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is trending as investors rotate toward defensive, dividend-focused assets, viewing the fund as a stable "anchor" amidst broader market volatility. The community is actively discussing the ETF's resilience on red market days, with long-term holders emphasizing the power of compounding dividends and reliable cash flow over high-growth speculative plays.

Amphenol Corp. engages in the design, manufacture, and marketing of electrical, electronic and fiber optic connectors, interconnect systems, antennas, sensors and sensor-based products, and specialty cable. It operates through the following segments: Harsh Environment Solutions, Communications Solutions, and Interconnect and Sensor Systems. The Harsh Environment Solutions segment manufactures and markets a broad range of ruggedized interconnect products, including connectors and interconnect systems, printed circuits and printed circuit assemblies, and other products. The Communications Solutions segment focuses on the design, manufacture, and marketing of connector and interconnect systems, including radio frequency, power, fiber optic, and other products, together with antennas. The Interconnect and Sensor Systems segment is involved in the design, manufacture, and marketing of sensors, sensor-based systems, connectors, and value-add interconnect systems. The company was founded by Schmitt J. Arthur in 1932 and is headquartered in Wallingford, CT.

Amphenol Corp. - Ordinary Shares - Class A

Amphenol is currently trending as investors weigh strong Q1 earnings results, featuring record sales and revenue beats, against concerns over elevated P/E valuations and broader market volatility. While the community remains divided between those capitalizing on the company's critical role in AI and wireless infrastructure and those skeptical of current price multiples, the underlying demand signals in order flow continue to drive intense discussion.

Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY.

Citigroup Inc

Citigroup Inc. is trending as it hits fresh 52-week highs, driven by strong institutional momentum, consistent corporate buybacks, and investor optimism surrounding its multi-year strategic transformation under CEO Jane Fraser. The community is actively debating the sustainability of this parabolic rally, weighing the bank's improved operational efficiency and capital strength against concerns that the rapid price ascent may be overextended.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Elicio Therapeutics Inc.

Elicio Therapeutics Inc

Elicio Therapeutics is trending as investors focus on the company's progress with ELI-002, a cancer vaccine candidate targeting KRAS-mutant solid tumors, while discussing potential risks related to cash runway and future financing needs. Community sentiment remains split between excitement over strong preliminary clinical data and concerns regarding the necessity of capital raises or dilution to fund upcoming phase 3 trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organogenesis (ORGO) Projected to Post Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-organogenesis-holdings-inc-stock...

Organogenesis (NASDAQ:ORGO) Trading Up 1.7% - Time to Buy?

Organogenesis (NASDAQ:ORGO) Shares Up 1.7% - What's Next...

<ul class="summary-bullets"><li>ReNu is a cryopreserved, amniotic suspension allograft.</li><li>The company decided to initiate a rolling application for ReNu following the completion of a meeting with the FDA.</li><li>The treatment received FDA’s Regenerative Medicine Advanced Therapy (RMAT)-designation in 2021.</li></ul> Shares of Organogenesis Holdings Inc. (ORGO) jumped 22% in Monday’s extended trading hours after the company said that it met with the U.S. Food and Drug Administration (FDA), and now plans to initiate seeking approval for its experimental treatment ReNu before the end of December.The company is seeking approval for ReNu in the treatment of knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.ReNu is a cryopreserved, amniotic suspension allograft. It provides anti-inflammatory, growth factor, and cellular components, offering a non-surgical alternative to reduce inflammation, alleviate pain, and enhance joint function. The treatment received FDA’s Regenerative Medicine Advanced Therapy (RMAT)-designation in 2021.<h2 class="st-heading-2">ReNu Application</h2>The company decided to initiate a rolling application for ReNu following the completion of a meeting with the FDA.“We are excited about the outcome of our FDA meeting and reaching this important milestone in the ReNu program. We are pleased the ReNu clinical development program consisting of two large Phase 3 randomized controlled trials (RCT), extensive commercial history and Regenerative Medicine Advanced Therapy (RMAT)-designation is appropriate for BLA submission,” said Patrick Bilbo, Chief Operating Officer of Organogenesis.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ORGO stock stayed within the ‘neutral’ territory while message volume remained at ‘normal’ levels.According to data from Koyfin, the sole analyst covering ORGO rated it ‘Buy’ with a $8 price target that implies a potential upside of about 257% from current trading levels.<a href="https://stocktwits.com/symbol/ORGO">ORGO stock</a> has fallen 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/neurocrine-soleno-deal-garners-wall-street-praise/cZJ4wmmRIYV">Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment 

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.

Equity

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.


Organogenesis (NASDAQ:ORGO) Receives "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $8.00 price objective on shares of Organogenesis in a research report on Thursday...

Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO

Assenagon Asset Management S.A. raised its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities...

Organogenesis $ORGO Shares Acquired by First Light Asset Management LLC

First Light Asset Management LLC lifted its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 10.6% during the 3rd quarter, according to the company in its most recent filing with the...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys 5,000 Shares of Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz purchased 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $2.68...

Michael Joseph Driscoll Buys 10,000 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll purchased 10,000 shares of the business's stock in a transaction on Monday, March 9th. The shares were purchased at an...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz acquired 5,000 shares of the firm's stock in a transaction on Monday, March 9th. The shares were acquired at an average price...

Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Purchases 10,000 Shares of Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll bought 10,000 shares of the firm's stock in a transaction dated Monday, March 9th. The stock was purchased at an average...

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

ORGO
Organogenesis Holdings Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ORGO News

ORGOOrganogenesis Holdings Inc - Ordinary Shares - Class A